• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

两性霉素B的体外药代动力学/药效学建模与模拟 针对……

In Vitro Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Amphotericin B against .

作者信息

Caballero Unai, Eraso Elena, Pemán Javier, Quindós Guillermo, Vozmediano Valvanera, Schmidt Stephan, Jauregizar Nerea

机构信息

Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.

Department of Immunology, Microbiology and Parasitology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.

出版信息

Pharmaceutics. 2021 Oct 22;13(11):1767. doi: 10.3390/pharmaceutics13111767.

DOI:10.3390/pharmaceutics13111767
PMID:34834182
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8624019/
Abstract

The aims of this study were to characterize the antifungal activity of amphotericin B against in a static in vitro system and to evaluate different dosing schedules and MIC scenarios by means of semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation. A two-compartment model consisting of a drug-susceptible and a drug-resistant subpopulation successfully characterized the time-kill data and a modified E sigmoidal model best described the effect of the drug. The model incorporated growth rate constants for both subpopulations, a death rate constant and a transfer constant between both compartments. Additionally, the model included a parameter to account for the delay in growth in the absence or presence of the drug. Amphotericin B displayed a concentration-dependent fungicidal activity. The developed PK/PD model was able to characterize properly the antifungal activity of amphotericin B against . Finally, simulation analysis revealed that none of the simulated standard dosing scenarios of 0.6, 1 and 1.5 mg/kg/day over a week treatment showed successful activity against infection. Simulations also pointed out that an MIC of 1 mg/L would be linked to treatment failure for invasive infections and therefore, the resistance rate to amphotericin B may be higher than previously reported.

摘要

本研究的目的是在静态体外系统中表征两性霉素B对[具体对象未明确]的抗真菌活性,并通过半机制药代动力学/药效学(PK/PD)建模和模拟评估不同的给药方案和最低抑菌浓度(MIC)情况。一个由药物敏感亚群和耐药亚群组成的二室模型成功地表征了时间-杀菌数据,并且一个修正的E型 sigmoid 模型能最好地描述药物的作用。该模型纳入了两个亚群的生长速率常数、一个死亡率常数以及两个隔室之间的转移常数。此外,该模型包含一个参数以说明在有或无药物情况下生长的延迟。两性霉素B表现出浓度依赖性杀菌活性。所建立的PK/PD模型能够恰当地表征两性霉素B对[具体对象未明确]的抗真菌活性。最后,模拟分析表明,在为期一周的治疗中,模拟的0.6、1和1.5mg/kg/天的标准给药方案均未显示出对[具体感染未明确]感染的成功活性。模拟还指出,对于[具体侵袭性感染未明确],MIC为1mg/L将与治疗失败相关,因此,对两性霉素B的耐药率可能高于先前报道。

相似文献

1
In Vitro Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Amphotericin B against .两性霉素B的体外药代动力学/药效学建模与模拟 针对……
Pharmaceutics. 2021 Oct 22;13(11):1767. doi: 10.3390/pharmaceutics13111767.
2
Defining Optimal Doses of Liposomal Amphotericin B Against Candida auris: Data From an In Vitro Pharmacokinetic/Pharmacodynamic Model.定义脂质体两性霉素 B 对抗耳念珠菌的最佳剂量:来自体外药代动力学/药效学模型的数据。
J Infect Dis. 2024 Feb 14;229(2):599-607. doi: 10.1093/infdis/jiad583.
3
In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against .两性霉素B与阿尼芬净或卡泊芬净联合应用对……的体外相互作用及杀菌动力学
Pharmaceutics. 2021 Aug 25;13(9):1333. doi: 10.3390/pharmaceutics13091333.
4
Antifungal activity and killing kinetics of anidulafungin, caspofungin and amphotericin B against Candida auris.抗真菌药物阿尼芬净、卡泊芬净和两性霉素 B 对耳念珠菌的抗真菌活性和杀菌动力学。
J Antimicrob Chemother. 2019 Aug 1;74(8):2295-2302. doi: 10.1093/jac/dkz178.
5
Activities of nine antifungal agents against Candida auris biofilms.九种抗真菌药物对耳念珠菌生物膜的活性。
Mycoses. 2021 Apr;64(4):381-384. doi: 10.1111/myc.13223. Epub 2020 Dec 13.
6
In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.在人血清白蛋白存在的情况下,两性霉素B去氧胆酸盐快速输注与持续输注对念珠菌属的体外药效学研究
J Antimicrob Chemother. 2006 Feb;57(2):288-93. doi: 10.1093/jac/dki467. Epub 2005 Dec 30.
7
Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak.针对来自纽约疫情的多重耐药耳念珠菌分离株的抗真菌药物联合评估
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02195-19.
8
Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.使用体外药代动力学-药效学模型优化抗曲霉病的多烯-唑联合疗法。
Antimicrob Agents Chemother. 2015 Jul;59(7):3973-83. doi: 10.1128/AAC.05035-14. Epub 2015 Apr 20.
9
Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.侵袭性耳念珠菌感染治疗的药效学优化
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00791-17. Print 2017 Aug.
10
Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model.采用半机制药代动力学/药效学模型评价维替米星与头孢他啶联合抗铜绿假单胞菌的体外协同作用。
Int J Antimicrob Agents. 2015 Feb;45(2):151-60. doi: 10.1016/j.ijantimicag.2014.09.017. Epub 2014 Nov 1.

引用本文的文献

1
Collateral sensitivity counteracts the evolution of antifungal drug resistance in Candida auris.Candida auris 中的共敏现象可拮抗抗真菌药物耐药性的进化。
Nat Microbiol. 2024 Nov;9(11):2954-2969. doi: 10.1038/s41564-024-01811-w. Epub 2024 Oct 29.
2
Novel thiazolinyl-picolinamide-based palladium(II) complex extenuates the virulence and biofilms of vulvovaginal candidiasis (VVC) causing Candida.新型噻唑啉基-吡啶甲酰胺基钯(II)配合物减轻导致阴道念珠菌病 (VVC) 的念珠菌的毒力和生物膜。
Int Microbiol. 2024 Oct;27(5):1527-1539. doi: 10.1007/s10123-024-00497-8. Epub 2024 Mar 11.
3
Defining Optimal Doses of Liposomal Amphotericin B Against Candida auris: Data From an In Vitro Pharmacokinetic/Pharmacodynamic Model.

本文引用的文献

1
Fungal co-infection in COVID-19 patients: Should we be concerned?新冠病毒感染患者中的真菌合并感染:我们应予以关注吗?
Rev Iberoam Micol. 2020 Apr-Jun;37(2):41-46. doi: 10.1016/j.riam.2020.07.001. Epub 2020 Sep 14.
2
How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST).如何根据修订后的临床折点 v.10.0 欧洲抗菌药物敏感性试验委员会 (EUCAST) 来解释抗真菌化合物的 MIC 值。
Clin Microbiol Infect. 2020 Nov;26(11):1464-1472. doi: 10.1016/j.cmi.2020.06.007. Epub 2020 Jun 17.
3
Review on Antifungal Resistance Mechanisms in the Emerging Pathogen .
定义脂质体两性霉素 B 对抗耳念珠菌的最佳剂量:来自体外药代动力学/药效学模型的数据。
J Infect Dis. 2024 Feb 14;229(2):599-607. doi: 10.1093/infdis/jiad583.
4
Model-Informed Precision Dosing (MIPD).模型指导的精准给药(MIPD)。
Pharmaceutics. 2022 Dec 6;14(12):2731. doi: 10.3390/pharmaceutics14122731.
5
In Vivo Efficacy of Amphotericin B against Four Clades.两性霉素B对四个进化枝的体内疗效
J Fungi (Basel). 2022 May 11;8(5):499. doi: 10.3390/jof8050499.
新兴病原体抗真菌耐药机制综述
Front Microbiol. 2019 Nov 29;10:2788. doi: 10.3389/fmicb.2019.02788. eCollection 2019.
4
[GEMICOMED/GEIRAS-SEIMC recommendations for the management of Candida auris infection and colonization].[GEMICOMED/GEIRAS-SEIMC关于耳念珠菌感染和定植管理的建议]
Rev Iberoam Micol. 2019 Jul-Sep;36(3):109-114. doi: 10.1016/j.riam.2019.06.001. Epub 2019 Nov 3.
5
Control of Candida auris in healthcare institutions: Outcome of an International Society for Antimicrobial Chemotherapy expert meeting.医疗机构中耳念珠菌的控制:国际抗菌化疗学会专家会议的结果。
Int J Antimicrob Agents. 2019 Oct;54(4):400-406. doi: 10.1016/j.ijantimicag.2019.08.013. Epub 2019 Aug 13.
6
Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candidemia Secondary to Chronic Candiduria.慢性念珠菌尿继发复发性念珠菌血症患者中高水平棘白菌素耐药性的产生
Open Forum Infect Dis. 2019 Jun 1;6(7):ofz262. doi: 10.1093/ofid/ofz262. eCollection 2019 Jul.
7
Candida auris and multidrug resistance: Defining the new normal.耳念珠菌和多重耐药性:定义新常态。
Fungal Genet Biol. 2019 Oct;131:103243. doi: 10.1016/j.fgb.2019.103243. Epub 2019 Jun 20.
8
Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B.脂质体两性霉素 B 的临床药代动力学、药效学、安全性和疗效。
Clin Infect Dis. 2019 May 2;68(Suppl 4):S260-S274. doi: 10.1093/cid/ciz076.
9
Antifungal activity and killing kinetics of anidulafungin, caspofungin and amphotericin B against Candida auris.抗真菌药物阿尼芬净、卡泊芬净和两性霉素 B 对耳念珠菌的抗真菌活性和杀菌动力学。
J Antimicrob Chemother. 2019 Aug 1;74(8):2295-2302. doi: 10.1093/jac/dkz178.
10
The continuous changes in the aetiology and epidemiology of invasive candidiasis: from familiar Candida albicans to multiresistant Candida auris.侵袭性念珠菌病病因学和流行病学的持续变化:从熟悉的白色念珠菌到多药耐药的耳念珠菌。
Int Microbiol. 2018 Sep;21(3):107-119. doi: 10.1007/s10123-018-0014-1. Epub 2018 Jul 6.